{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Malignant&page=11", "query": { "condition": "Glioma, Malignant", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 763, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Malignant&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Malignant&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:19:14.436Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02967380", "title": "Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Anaplastic (Malignant) Meningioma", "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Choroid Plexus Neoplasm", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade II Meningioma", "Adult Medulloblastoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pineal Gland Astrocytoma", "Adult Pineoblastoma", "Adult Primary Melanocytic Lesion of Meninges", "Adult Supratentorial Primitive Neuroectodermal Tumor", "Malignant Adult Intracranial Hemangiopericytoma", "Metastatic Malignant Neoplasm in the Brain", "Multiple Sclerosis", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Gadobenate Dimeglumine", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadopentetate Dimeglumine", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2011-12-14", "completion_date": "2015-10-14", "has_results": false, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02967380" }, { "nct_id": "NCT00002752", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Metastatic Cancer" ], "interventions": [ { "name": "iodine I 131 monoclonal antibody 81C6", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": null, "start_date": "1993-02", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002752" }, { "nct_id": "NCT03257631", "title": "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasms", "Medulloblastoma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 53, "start_date": "2017-09-18", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 6, "location_summary": "Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257631" }, { "nct_id": "NCT03576612", "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma, Malignant" ], "interventions": [ { "name": "AdV-tk", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-02-27", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576612" }, { "nct_id": "NCT02558335", "title": "CTCs for High Grade Glioma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage III and IV Glioma Patients" ], "interventions": [], "intervention_types": [], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-04", "completion_date": "2020-04", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558335" }, { "nct_id": "NCT04943848", "title": "rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant" ], "interventions": [ { "name": "rHSC-DIPGVax", "type": "BIOLOGICAL" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Zalifrelimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Months to 18 Years" }, "enrollment_count": 36, "start_date": "2022-01-10", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 3, "location_summary": "Orange, California • Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04943848" }, { "nct_id": "NCT03860376", "title": "Ex Vivo Drug Sensitivity Testing and Mutation Profiling", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Refractory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Hodgkin Lymphoma", "Refractory Childhood Malignant Germ Cell Neoplasm", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Brainstem Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Gliosarcoma", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [], "intervention_types": [], "sponsor": "Florida International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 25, "start_date": "2019-02-21", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860376" }, { "nct_id": "NCT02540135", "title": "Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "High Grade Malignant Neoplasm", "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "fluorescein", "type": "OTHER" }, { "name": "intraoperative MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-03-01", "completion_date": "2018-07-18", "has_results": false, "last_update_posted_date": "2018-07-20", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02540135" }, { "nct_id": "NCT06838676", "title": "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Gliomas (DIPG)", "Progressive DIPG", "Refractory DIPG", "Recurrent DIPG", "H3K27-altered High Grade Glioma" ], "interventions": [ { "name": "ACT001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 60, "start_date": "2025-07-10", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 12, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06838676" }, { "nct_id": "NCT00005952", "title": "Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Head and Neck Cancer", "Kidney Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 30, "start_date": "2000-08", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-14T17:19:14.436Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005952" } ] }